ATE443721T1 - Lipoprotein-regulierende medikamente - Google Patents

Lipoprotein-regulierende medikamente

Info

Publication number: ATE443721T1
Authority: AT; Austria
Prior art keywords: lsr; purified; ffa; isolated; binds
Prior art date: 1997-08-06

Application number

AT07120518T

Other languages

English (en)

Inventor

Bernard Bihain

Lydie Bougueleret

Frances Yen-Potin

Original Assignee

Merck Serono Biodevelopment

Inst Nat Sante Rech Med

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-06

Filing date

1998-08-06

Publication date

2009-10-15

1997-08-06 Priority claimed from FR9710088A external-priority patent/FR2767136B1/fr

1998-08-06 Application filed by Merck Serono Biodevelopment, Inst Nat Sante Rech Med filed Critical Merck Serono Biodevelopment

2009-10-15 Application granted granted Critical

2009-10-15 Publication of ATE443721T1 publication Critical patent/ATE443721T1/de

Links

239000003814 drug Substances 0.000 title 1
229940079593 drug Drugs 0.000 title 1
108010077695 lipolysis-stimulated receptor Proteins 0.000 abstract 7
235000021588 free fatty acids Nutrition 0.000 abstract 3
150000007523 nucleic acids Chemical class 0.000 abstract 3
102000004127 Cytokines Human genes 0.000 abstract 1
108090000695 Cytokines Proteins 0.000 abstract 1
102000016267 Leptin Human genes 0.000 abstract 1
108010092277 Leptin Proteins 0.000 abstract 1
108090001030 Lipoproteins Proteins 0.000 abstract 1
102000004895 Lipoproteins Human genes 0.000 abstract 1
238000010367 cloning Methods 0.000 abstract 1
239000013604 expression vector Substances 0.000 abstract 1
229940127121 immunoconjugate Drugs 0.000 abstract 1
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract 1
229940039781 leptin Drugs 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
238000012216 screening Methods 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Zoology (AREA)
Cardiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Obesity (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT07120518T 1997-08-06 1998-08-06 Lipoprotein-regulierende medikamente ATE443721T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9710088A FR2767136B1 (fr)	1997-08-06	1997-08-06	Recepteur complexe lsr, activite, clonage, et applications au diagnostic, a la prevention et/ou au traitement de l'obesite et des risques ou complications associes
FR9805032A FR2767135B1 (fr)	1997-08-06	1998-04-22	Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes

Publications (1)

Publication Number	Publication Date
ATE443721T1 true ATE443721T1 (de)	2009-10-15

Family

ID=26233732

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
AT98936611T ATE256146T1 (de)	1997-08-06	1998-08-06	Klonierung und verwendung des lsr-rezeptors
AT07120518T ATE443721T1 (de)	1997-08-06	1998-08-06	Lipoprotein-regulierende medikamente
AT98936610T ATE378354T1 (de)	1997-08-06	1998-08-06	Lipoprotein-regulierende arzneimittel

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT98936611T ATE256146T1 (de)	1997-08-06	1998-08-06	Klonierung und verwendung des lsr-rezeptors

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT98936610T ATE378354T1 (de)	1997-08-06	1998-08-06	Lipoprotein-regulierende arzneimittel

Country Status (13)

Country	Link
US (8)	US6344441B1 (de)
EP (4)	EP1003783B1 (de)
JP (3)	JP2001512746A (de)
AT (3)	ATE256146T1 (de)
AU (2)	AU754942B2 (de)
CA (2)	CA2298849A1 (de)
CY (1)	CY1107808T1 (de)
DE (3)	DE69820419T2 (de)
DK (2)	DK0964870T3 (de)
ES (2)	ES2210786T3 (de)
FR (1)	FR2767135B1 (de)
PT (2)	PT1003783E (de)
WO (2)	WO1999007737A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6469158B1 (en) *	1992-05-14	2002-10-22	Ribozyme Pharmaceuticals, Incorporated	Synthesis, deprotection, analysis and purification of RNA and ribozymes
US6525174B1 (en)	1997-06-06	2003-02-25	Human Genome Sciences, Inc.	Precerebellin-like protein
FR2767135B1 (fr)	1997-08-06	2002-07-12	Genset Sa	Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
US20020106728A1 (en) *	2000-06-20	2002-08-08	Genentech, Inc.	NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
WO2000026363A1 (en) *	1998-11-04	2000-05-11	Genset	GENOMIC AND COMPLETE cDNA SEQUENCES OF HUMAN ADIPOCYTE-SPECIFIC APM1 AND BIALLELIC MARKERS THEREOF
WO2000047772A2 (en)	1999-02-10	2000-08-17	Genset	Polymorphic markers of the lsr gene
MXPA01010540A (es) *	1999-04-20	2002-06-04	Zymogenetics Inc	Proteina homologa zacrp2 relacionada al complemento de adipocitos.
AU4468800A (en) *	1999-04-20	2000-11-02	Zymogenetics Inc.	Adipocyte complement related protein homolog zacrp3
CA2388417A1 (en) *	1999-09-22	2001-03-29	Genset	Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
WO2001032868A1 (en) *	1999-11-04	2001-05-10	Genset	Apm1 biallelic markers and uses thereof
US20020058617A1 (en)	2000-01-14	2002-05-16	Joachim Fruebis	OBG3 globular head and uses thereof for decreasing body mass
US6989367B2 (en)	2000-01-14	2006-01-24	Genset S.A.	OBG3 globular head and uses thereof
US6566332B2 (en)	2000-01-14	2003-05-20	Genset S.A.	OBG3 globular head and uses thereof for decreasing body mass
ATE405655T1 (de) *	2000-01-14	2008-09-15	Serono Genetics Inst Sa	Obg3 globularekopf und seine verwendungen zur reduzierung des körpersgewichtes
US6579852B2 (en)	2000-01-14	2003-06-17	Genset S.A.	OBG3 globular head and uses thereof for decreasing body mass
US7338787B2 (en)	2000-01-14	2008-03-04	Serono Genetics Institute S.A.	Nucleic acids encoding OBG3 globular head and uses thereof
WO2001092330A2 (en) *	2000-05-31	2001-12-06	Genset S.A.	Use of acrp30 globular head to promote increases in muscle mass and muscle differentiation
IL153927A0 (en) *	2000-07-18	2003-07-31	Genset Sa	Genomic maps comprising biallelic markers, new such markers and the use of biallelic markers
MXPA03007672A (es) *	2001-02-26	2004-11-12	Univ Sydney	Metodo para mejorar la funcion de crecimiento de un animal.
US20020132773A1 (en) *	2001-03-14	2002-09-19	Oklahoma Medical Research Foundation	Methods for reducing fat by administration of adiponectin
JP4547696B2 (ja) *	2001-06-07	2010-09-22	第一三共株式会社	肝硬変予防・治療剤
WO2003011324A1 (en) *	2001-07-31	2003-02-13	Genset S.A.	Agonists and antagonists of moxifin for the treatment of metabolic disorders
EP1418934A1 (de) *	2001-08-02	2004-05-19	Genset S.A.	Agonisten und antagonisten von xobesin zur behandlung von stoffwechselerkrankungen
WO2003041738A1 (en) *	2001-11-15	2003-05-22	Genset S.A.	Treatment of metabolic disorders with xitar agonists and antagonists
AU2002339691A1 (en) *	2001-11-29	2003-06-10	Genset	Agonists and antagonists of prolixin for the treatment of metabolic disorders
CA2473781A1 (en) *	2002-01-18	2003-07-31	Protemix Corporation Limited	Glycoisoforms of adiponectin and uses thereof
US6852693B2 (en)	2002-02-07	2005-02-08	Blm Group	Compositions and methods for promoting lipid mobilization in humans
US7419955B2 (en) *	2002-05-24	2008-09-02	Japan Science And Technology Agency	Method for treating arteriosclerosis
US7459433B2 (en)	2002-05-31	2008-12-02	Serono Genetics Institute, S.A.	Homotrimeric extended OBG3 globular head and uses thereof
WO2004063711A2 (en) *	2003-01-09	2004-07-29	Beth Israel Deaconess Medical Center, Inc.	Use of adiponectin to diagnose and treat malignancy
US8147561B2 (en)	2004-02-26	2012-04-03	Endosphere, Inc.	Methods and devices to curb appetite and/or reduce food intake
US8585771B2 (en)	2004-02-26	2013-11-19	Endosphere, Inc.	Methods and devices to curb appetite and/or to reduce food intake
US7931693B2 (en) *	2004-02-26	2011-04-26	Endosphere, Inc.	Method and apparatus for reducing obesity
US20060127468A1 (en) *	2004-05-19	2006-06-15	Kolodney Michael S	Methods and related compositions for reduction of fat and skin tightening
EP1830873A4 (de) *	2004-12-10	2008-04-02	Protemix Corp Ltd	Glyponectin (glykosyliertes adiponektin) zur behandlung von krankheiten und zuständen
US7592423B2 (en) *	2005-01-07	2009-09-22	Xencor, Inc.	Globular adiponectin variants
US7749956B2 (en) *	2005-01-07	2010-07-06	Xencor, Inc.	Method of treatment using adiponectin variants
US7678886B2 (en) *	2005-01-07	2010-03-16	Xencor, Inc.	Pharmaceutical compositions of adiponectin variants and methods of storage
JP2008526885A (ja) *	2005-01-07	2008-07-24	ゼンコア	アディポネクチン変異体
US7964557B2 (en) *	2005-03-28	2011-06-21	University Of Louisville Research Foundation, Inc.	Inhibition of wet type age related macular degeneration (AMD) by adiponectin or acrp 30
US20070054359A1 (en) *	2005-07-11	2007-03-08	Jonathan Zalevsky	Rational Chemical Modification of Adiponectin Variants
CA2616912A1 (en) *	2005-07-29	2007-02-08	Laboratoires Serono S.A.	Use of the globular domain of acrp30 for the preparation of a medicament for the prevention and/or treatment of thrombosis-related diseases
US9060835B2 (en)	2006-05-26	2015-06-23	Endosphere, Inc.	Conformationally-stabilized intraluminal device for medical applications
US20110137227A1 (en)	2007-07-16	2011-06-09	Mckinley James T	Methods and devices for delivering or delaying lipids within a duodenum
JP5242701B2 (ja) *	2007-12-19	2013-07-24	イーライリリーアンドカンパニー	肥満症の薬物療法に対する反応性を予測するための方法
JP5429736B2 (ja) *	2009-04-13	2014-02-26	国立大学法人神戸大学	タイトジャンクション調節剤
MX363465B (es)	2011-02-18	2019-03-25	Kythera Biopharmaceuticals Inc	Tratamiento de la grasa submental.
NZ713461A (en)	2011-04-15	2017-02-24	Compugen Ltd	Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
IN2014KN00920A (de) *	2012-06-21	2015-10-09	Compugen Ltd
CN104004066B (zh) *	2013-02-26	2017-05-31	上海市第一人民医院	预防或抑制炎症反应和血管新生的小分子多肽及其应用
US9682123B2 (en)	2013-12-20	2017-06-20	The Trustees Of Columbia University In The City Of New York	Methods of treating metabolic disease
US10174111B2 (en)	2013-12-27	2019-01-08	National University Corporation Kochi University	Therapeutic drug for malignant tumors
US12331320B2 (en)	2018-10-10	2025-06-17	The Research Foundation For The State University Of New York	Genome edited cancer cell vaccines
CN120643715A (zh) *	2025-06-16	2025-09-16	滨州医学院	巨噬细胞Angulin-1在制备预防和/或治疗动脉粥样硬化及相关疾病的药物、诊断产品中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US77051A (en) *		1868-04-21		peters
US67881A (en) *		1867-08-20		Geobge p
US111500A (en) *		1871-01-31		Improvement in repeating fire-arms
US5543394A (en) *	1986-07-01	1996-08-06	Genetics Institute, Inc.	Bone morphogenetic protein 5(BMP-5) compositions
US5194596A (en) *	1989-07-27	1993-03-16	California Biotechnology Inc.	Production of vascular endothelial cell growth factor
US5350836A (en) *	1989-10-12	1994-09-27	Ohio University	Growth hormone antagonists
NL9100132A (nl) *	1991-01-25	1992-08-17	Ingeny Bv	Werkwijze voor het detecteren van dna sequentievariatie.
US5270170A (en)	1991-10-16	1993-12-14	Affymax Technologies N.V.	Peptide library and screening method
US6140466A (en)	1994-01-18	2000-10-31	The Scripps Research Institute	Zinc finger protein derivatives and methods therefor
US5691447A (en)	1995-03-24	1997-11-25	Tanox Biosystems, Inc.	GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
FR2733762B1 (fr)	1995-05-02	1997-08-01	Genset Sa	Methode de couplage specifique de la coiffe de l'extremite 5' d'un fragment d'arnm et preparation d'arnm et d'adnc complet
US5869330A (en) *	1995-06-05	1999-02-09	Whitehead Institute For Biomedical Research	DNA encoding a novel serum protein produced exclusively in adipocytes
WO1997027286A1 (en)	1996-01-23	1997-07-31	Progenitor, Inc.	Methods for using the obese gene and its gene product to stimulate hematopoietic development
US6116126A (en)	1996-07-10	2000-09-12	Van Den Bulcke; Marc	Method and machine for making profile pieces
US6126939A (en) *	1996-09-03	2000-10-03	Yeda Research And Development Co. Ltd.	Anti-inflammatory dipeptide and pharmaceutical composition thereof
WO1998020165A2 (en)	1996-11-06	1998-05-14	Whitehead Institute For Biomedical Research	Biallelic markers
HUP0003762A3 (en) *	1997-07-18	2005-11-28	Zymogenetics Inc	Adipocyte-specific protein homologs
FR2767135B1 (fr) *	1997-08-06	2002-07-12	Genset Sa	Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
WO1999010492A1 (en)	1997-08-26	1999-03-04	Zymogenetics, Inc.	Adipocyte-specific protein homologs
JP3538711B2 (ja) *	1997-10-29	2004-06-14	大塚製薬株式会社	平滑筋増殖抑制組成物、動脈硬化症診断方法及びそのキット
US6579852B2 (en)	2000-01-14	2003-06-17	Genset S.A.	OBG3 globular head and uses thereof for decreasing body mass
US6566332B2 (en)	2000-01-14	2003-05-20	Genset S.A.	OBG3 globular head and uses thereof for decreasing body mass
US20020058617A1 (en)	2000-01-14	2002-05-16	Joachim Fruebis	OBG3 globular head and uses thereof for decreasing body mass
US6989367B2 (en)	2000-01-14	2006-01-24	Genset S.A.	OBG3 globular head and uses thereof
US20030224501A1 (en)	2000-03-17	2003-12-04	Young Paul E.	Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US20030215836A1 (en)	2000-03-17	2003-11-20	Young Paul E.	Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US6867189B2 (en)	2001-07-26	2005-03-15	Genset S.A.	Use of adipsin/complement factor D in the treatment of metabolic related disorders
WO2003011324A1 (en)	2001-07-31	2003-02-13	Genset S.A.	Agonists and antagonists of moxifin for the treatment of metabolic disorders
EP1418934A1 (de)	2001-08-02	2004-05-19	Genset S.A.	Agonisten und antagonisten von xobesin zur behandlung von stoffwechselerkrankungen
AU2002339691A1 (en)	2001-11-29	2003-06-10	Genset	Agonists and antagonists of prolixin for the treatment of metabolic disorders

1998
- 1998-04-22 FR FR9805032A patent/FR2767135B1/fr not_active Expired - Fee Related
- 1998-08-06 DK DK98936611T patent/DK0964870T3/da active
- 1998-08-06 WO PCT/IB1998/001257 patent/WO1999007737A2/fr not_active Ceased
- 1998-08-06 AT AT98936611T patent/ATE256146T1/de active
- 1998-08-06 JP JP2000506238A patent/JP2001512746A/ja active Pending
- 1998-08-06 DE DE69820419T patent/DE69820419T2/de not_active Expired - Lifetime
- 1998-08-06 DE DE69838720T patent/DE69838720T2/de not_active Expired - Lifetime
- 1998-08-06 ES ES98936611T patent/ES2210786T3/es not_active Expired - Lifetime
- 1998-08-06 ES ES98936610T patent/ES2296339T3/es not_active Expired - Lifetime
- 1998-08-06 AU AU85563/98A patent/AU754942B2/en not_active Ceased
- 1998-08-06 DE DE69841186T patent/DE69841186D1/de not_active Expired - Lifetime
- 1998-08-06 EP EP98936610A patent/EP1003783B1/de not_active Expired - Lifetime
- 1998-08-06 PT PT98936610T patent/PT1003783E/pt unknown
- 1998-08-06 EP EP98936611A patent/EP0964870B1/de not_active Expired - Lifetime
- 1998-08-06 AU AU85564/98A patent/AU745607C/en not_active Ceased
- 1998-08-06 CA CA002298849A patent/CA2298849A1/en not_active Abandoned
- 1998-08-06 EP EP07120518A patent/EP1903057B1/de not_active Expired - Lifetime
- 1998-08-06 EP EP03102647A patent/EP1375516A3/de not_active Withdrawn
- 1998-08-06 US US09/485,316 patent/US6344441B1/en not_active Expired - Fee Related
- 1998-08-06 AT AT07120518T patent/ATE443721T1/de not_active IP Right Cessation
- 1998-08-06 JP JP51192099A patent/JP3726969B2/ja not_active Expired - Lifetime
- 1998-08-06 AT AT98936610T patent/ATE378354T1/de not_active IP Right Cessation
- 1998-08-06 US US09/269,939 patent/US6635431B1/en not_active Expired - Fee Related
- 1998-08-06 DK DK98936610T patent/DK1003783T3/da active
- 1998-08-06 CA CA002274302A patent/CA2274302A1/fr not_active Abandoned
- 1998-08-06 WO PCT/IB1998/001256 patent/WO1999007736A2/en not_active Ceased
- 1998-08-06 PT PT98936611T patent/PT964870E/pt unknown
2002
- 2002-01-29 US US10/060,845 patent/US6946444B2/en not_active Expired - Fee Related
- 2002-02-05 US US10/072,159 patent/US7220722B2/en not_active Expired - Fee Related
2003
- 2003-08-27 US US10/650,507 patent/US7291709B2/en not_active Expired - Fee Related
2004
- 2004-12-08 JP JP2004355464A patent/JP2005143508A/ja active Pending
2007
- 2007-04-30 US US11/741,979 patent/US20080249009A1/en not_active Abandoned
- 2007-09-27 US US11/862,842 patent/US7919091B2/en not_active Expired - Fee Related
- 2007-11-20 CY CY20071101489T patent/CY1107808T1/el unknown
2011
- 2011-02-03 US US13/020,359 patent/US20110165166A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU745607B2 (en)	2002-03-21
CA2274302A1 (fr)	1999-02-18
US20080249009A1 (en)	2008-10-09
EP1375516A3 (de)	2004-06-09
DE69841186D1 (de)	2009-11-05
DK0964870T3 (da)	2004-03-08
US6946444B2 (en)	2005-09-20
EP1903057A3 (de)	2008-06-25
US6635431B1 (en)	2003-10-21
EP1003783A2 (de)	2000-05-31
US20090263847A1 (en)	2009-10-22
US7220722B2 (en)	2007-05-22
US20040077051A1 (en)	2004-04-22
ATE378354T1 (de)	2007-11-15
JP2001512746A (ja)	2001-08-28
WO1999007736A3 (en)	1999-05-20
JP2005143508A (ja)	2005-06-09
DE69838720T2 (de)	2008-10-30
ES2296339T3 (es)	2008-04-16
US20020165154A1 (en)	2002-11-07
PT964870E (pt)	2004-02-27
AU8556498A (en)	1999-03-01
ATE256146T1 (de)	2003-12-15
US20110165166A1 (en)	2011-07-07
JP3726969B2 (ja)	2005-12-14
WO1999007737A2 (fr)	1999-02-18
JP2001512492A (ja)	2001-08-21
EP1375516A2 (de)	2004-01-02
EP0964870A2 (de)	1999-12-22
US7919091B2 (en)	2011-04-05
ES2210786T3 (es)	2004-07-01
EP0964870B1 (de)	2003-12-10
DE69838720D1 (de)	2007-12-27
US7291709B2 (en)	2007-11-06
EP1003783B1 (de)	2007-11-14
FR2767135A1 (fr)	1999-02-12
DE69820419T2 (de)	2004-11-25
DE69820419D1 (de)	2004-01-22
CA2298849A1 (en)	1999-02-18
AU8556398A (en)	1999-03-01
WO1999007737A3 (fr)	1999-06-10
DK1003783T3 (da)	2008-01-02
US6344441B1 (en)	2002-02-05
AU745607C (en)	2002-08-29
WO1999007736A2 (en)	1999-02-18
CY1107808T1 (el)	2013-06-19
EP1903057B1 (de)	2009-09-23
AU754942B2 (en)	2002-11-28
EP1903057A2 (de)	2008-03-26
FR2767135B1 (fr)	2002-07-12
US20020151498A1 (en)	2002-10-17
PT1003783E (pt)	2007-12-06

Legal Events

Date	Code	Title	Description
2010-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE443721T1 (de)	2009-10-15	Lipoprotein-regulierende medikamente
UA42760C2 (uk)	2001-11-15	Спосіб спрямування клітинної імунної відповіді проти віл-інфікованої клітини ссавця,білковий мембранозв'язаний химерний рецептор,днк,яка кодує химерний рецептор,вектор,що її містить
ATE25197T1 (de)	1987-02-15	Hybridproteinekodierende fusionierte gene, sie enthaltende klonierungsvektoren und deren verwendung.
DE69738432D1 (de)	2008-02-14	Targeting von adenoviren mit hilfe von konformationsbeschränkten peptidmotiven
DE69738514D1 (de)	2008-03-27	Verbesserte expressionsvektoren
FI104180B1 (fi)	1999-11-30	Menetelmä polypeptidin vasta-aineen ekä IL-4 välittämien tilojen hoitoon tarkoitetun seoksen valmistamiseksi
FI972390A0 (fi)	1997-06-05	Sytokiini nimeltä Lerk-7
ATE136908T1 (de)	1996-05-15	Peptide und antikörper, die die integrin- ligandbindung inhibieren
EA200000216A1 (ru)	2000-08-28	Белки, связывающие интерлейкин-18, их получение и применение
ATE541931T1 (de)	2012-02-15	Il-17-homologe polypeptide und ihre therapeutische verwendung
DE3587840D1 (de)	1994-07-14	Für das Polypeptid des T-Zellantigenreceptors kodierende Nukleinsäure.
DK230683A (da)	1983-11-26	Rekombinante dna-klonende vektorer til udtrykkelse af endogent protein
DE69824719D1 (de)	2004-07-29	Cytokinähnlicher faktor-7 aus säugetieren
DK1017715T3 (da)	2008-10-06	Kimært polypeptid der omfatter fragment B af shiga-toksin og peptider af terapeutisk interesse
DE69735716D1 (de)	2006-05-24	Kappa/mu ähnliche proteintyrosinphosphatase, proteintyrosinphosphatase lambda
NO860421L (no)	1986-02-06	Sammensmeltet gen som koder for et hybridprotein.
ATE317434T1 (de)	2006-02-15	Klonierung und expression von einer acetylcholin- durchlässigen ionenkanälen rezeptor-untereinheit
DE69837475D1 (de)	2007-05-16	Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
NO944887L (no)	1994-12-16	Monoklonale antistoffer mot glykoprotein
DK0901526T3 (da)	2007-09-10	Cortistatin: neuropeptider, sammensætninger og metoder
TR200000288T2 (tr)	2000-06-21	İnsülin C-peptidin rekombinan ekspresyonu.
FR2697850B1 (fr)	1994-12-02	Nouveaux polypeptides ayant une activité de récepteur opioïde, acides nucléiques codant pour ces polypeptides et utilisations.
DK0487229T3 (da)	1997-12-29	DNA, der koder for et protein, som binder til enhanceren for alfa-føtoproteingenet
DK1300417T3 (da)	2006-10-30	Secerneret og transmembrant polypeptid og nucleinsyre kodende derfor
DK1249491T3 (da)	2006-01-16	Nucleinsyre, der opformeres i humane tumorer samt beslægtede materialer og fremgangsmåder